首页> 外文OA文献 >Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program

【2h】

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program

机译：了解积极效益：Alemtuzumab在复发多发性硬化症中的风险概况：来自Alemtuzumab临床发展计划的观点

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Eva Havrdova; Jeffrey Cohen; Dana Horáková; Ivana Kovarova; Eva Meluzinova;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program [J] . Eva Havrdova, Jeffrey A Cohen, Dana Horakova, Therapeutics and Clinical Risk Management . 2017,第2期

机译：了解积极益处：复发性多发性硬化症中阿仑单抗的风险特征：来自阿仑单抗临床开发计划的观点
2. Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis [J] . Cristina Guarnera, Placido Bramanti, Emanuela Mazzon Therapeutics and Clinical Risk Management . 2017,第5期

机译：Alemtuzumab：复发缓解型多发性硬化症的疗效和风险评估
3. Severe Coombs Positive Autoimmune Hemolytic Anemia after Alemtuzumab Infusion for Relapsing Remitting Multiple Sclerosis What Can We Learn? [J] . Desai Parth Anil, Romere Chase Mathew, Nguyen Linda, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：严重的Coombs阳性自身免疫溶血性贫血后Alemtuzumab输注重复延迟多发性硬化，我们可以学到什么？
4. Discovering Potential Clinical Profiles o Multiple Sclerosis from Clinical and Pathological Free Text Data with Constrained Non-negative Matrix Factorization [C] . Jacopo Acquarelli, The Netherlands Brain Bank, Monica Bianchini, European conference on applications of evolutionary computation . 2016

机译：从具有约束力的非负矩阵分解的临床和病理学自由文本数据中发现多发性硬化症的潜在临床特征
5. Development of potential biomarkers to forecast treatment response and clinical relapses of multiple sclerosis by investigating the CNS-specific proteome fingerprint of experimental autoimmune encephalomyelitis [D] . Raphael, Itay 2016

机译：通过研究实验性自身免疫性脑脊髓炎的中枢神经系统特异性蛋白质组指纹图谱，开发潜在的生物标记物以预测多发性硬化症的治疗反应和临床复发
6. Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program [O] . Eva Havrdova, Jeffrey A Cohen, Dana Horakova, 2017

机译：了解积极益处：复发性多发性硬化症中阿仑单抗的风险特征：来自阿仑单抗临床开发计划的观点
7. The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective [O] . Raed Alroughani, Bart Van Wijmeersch, Jabber Al Khaboori, 2020

机译：Alemtuzumab在复发延迟多发性硬化症患者中的使用：海湾透视

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program

著录项

引文网络

相似文献

相关主题

期刊订阅